highly significantp < 0.001
After the first year of therapy, discontinuation due to an adverse event was low (∼3% per year) and among the patients who did not stop therapy or stopped it for a short time (≤30 days), the benefit of ticagrelor in terms of reduction of ischaemic events was highly significant (ticagrelor 60 mg bid vs placebo: HR 0.79, 95% CI 0.68-0.91; p < 0.001) 147 .